These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 23363459)
1. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. Lachaine J; Yen L; Beauchemin C; Hodgkins P BMC Gastroenterol; 2013 Jan; 13():23. PubMed ID: 23363459 [TBL] [Abstract][Full Text] [Related]
2. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213 [TBL] [Abstract][Full Text] [Related]
3. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789 [TBL] [Abstract][Full Text] [Related]
4. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database. Ota T; Takebe T; Shimizu Y; Orido T; Tanaka H; Nakamura S Digestion; 2024; 105(3):232-242. PubMed ID: 38527451 [TBL] [Abstract][Full Text] [Related]
6. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Moshkovska T; Stone MA; Smith RM; Bankart J; Baker R; Mayberry JF Inflamm Bowel Dis; 2011 Sep; 17(9):1874-81. PubMed ID: 21830265 [TBL] [Abstract][Full Text] [Related]
7. Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis. Lee J; Jee SR; Kim HW; Baek DH; Song GA; Moon W; Park SJ; Kim HJ; Lee JH; Park JH; Kim TO; PLoS One; 2019; 14(3):e0214129. PubMed ID: 30901362 [TBL] [Abstract][Full Text] [Related]
8. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. Nikolaus S; Schreiber S; Siegmund B; Bokemeyer B; Bästlein E; Bachmann O; Görlich D; Hofmann U; Schwab M; Kruis W J Crohns Colitis; 2017 Sep; 11(9):1052-1062. PubMed ID: 28486634 [TBL] [Abstract][Full Text] [Related]
9. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Boyle M; Ting A; Cury DB; Nanda K; Cheifetz AS; Moss A Inflamm Bowel Dis; 2015 Dec; 21(12):2873-8. PubMed ID: 26313693 [TBL] [Abstract][Full Text] [Related]
10. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Khan N; Abbas AM; Koleva YN; Bazzano LA Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878 [TBL] [Abstract][Full Text] [Related]
11. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519 [TBL] [Abstract][Full Text] [Related]
12. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Bello C; Belaiche J; Louis E; Reenaers C J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881 [TBL] [Abstract][Full Text] [Related]
13. Response to the letter of Gifford and Moss. Moshkovska T; Inflamm Bowel Dis; 2013 Feb; 19(2):E19-20. PubMed ID: 22180002 [No Abstract] [Full Text] [Related]
14. Comment on Moshkovska et al. Gifford A; Moss AC Inflamm Bowel Dis; 2013 Feb; 19(2):E19. PubMed ID: 22179973 [No Abstract] [Full Text] [Related]
15. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. Moss AC; Chaudhary N; Tukey M; Junior J; Cury D; Falchuk KR; Cheifetz AS J Crohns Colitis; 2010 Jun; 4(2):171-5. PubMed ID: 21122501 [TBL] [Abstract][Full Text] [Related]
16. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Moss AC; Lillis Y; Edwards George JB; Choudhry NK; Berg AH; Cheifetz AS; Horowitz G; Leffler DA Am J Gastroenterol; 2014 Dec; 109(12):1850-5. PubMed ID: 24913040 [TBL] [Abstract][Full Text] [Related]
17. Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Oliveira L; Cohen RD Drug Des Devel Ther; 2011 Feb; 5():111-6. PubMed ID: 21448448 [TBL] [Abstract][Full Text] [Related]
18. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Watanabe C; Nagahori M; Fujii T; Yokoyama K; Yoshimura N; Kobayashi T; Yamagami H; Kitamura K; Takashi K; Nakamura S; Naganuma M; Ishihara S; Esaki M; Yonezawa M; Kunisaki R; Sakuraba A; Kuji N; Miura S; Hibi T; Suzuki Y; Hokari R Dig Dis Sci; 2021 Feb; 66(2):577-586. PubMed ID: 32249373 [TBL] [Abstract][Full Text] [Related]
19. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Elkjaer M Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851 [TBL] [Abstract][Full Text] [Related]
20. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A Patient; 2012; 5(1):33-44. PubMed ID: 22077619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]